{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Overall survival is measured from entry onto study until death from any cause or until death or progression of disease, respectively.","groups":[{"description":"Rituximab: (i.v.) 375 mg/m\\^2 given the evening before blood brain barrier disruption(BBBD) procedure day 1 Carboplatin: (i.a.) 200 mg/m\\^2 /day x 2 days = 400 mg/m\\^2","id":"OG000","title":"Rituximab and Carboplatin"}],"populationDescription":"Data not collected due to low accrual and early termination.","reportingStatus":"POSTED","timeFrame":"5 years","title":"Number of Participants With Overall Survival Assessed by Clinical and Radiographic Response","type":"SECONDARY"}